BIAF BIAF
Company Profile ↓Company Overview
BIAF (BIAF) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 986.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $6.16M (-34.2% YoY); net profit $-14.91M.
- Trailing 12 Months Year-on-year growth — revenue -34.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 986.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 986.60% |
| 1 Year: | -34.18% |
Stock Price Performance
| 1 Year: | -94.19% |
| 6 Months: | -50.49% |
| 3 Months: | -73.77% |
| 1 Month: | -36.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.91 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 986.6% over 5 years.
CONS
- Trading 95.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 1.31K | 1.15K | 921 | 19.74K | 298.48K | 2.41M | 2.40M | 2.35M | 1.85M | 1.27M | 1.45M | 1.54M | 1.35M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 1.37M | 1.02M | 942.21K | 900.13K | 928.64K |
| Gross Profit | - | - | 1.16K | 1.00K | 834 | 18.50K | 223.78K | - | - | - | 485.74K | 252.88K | 503.86K | 638.69K | 422.89K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 3.11M | 2.77M | 2.80M | 3.83M | 4.04M |
| Operating Income | -526.29K | -727.04K | -684.12K | -976.16K | -1.56M | -1.78M | -2.29M | -1.95M | -2.09M | -1.97M | -2.63M | -2.52M | -2.29M | -3.19M | -3.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -2.48M | -3.91M | -4.93M | -3.00M | -3.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 15.48K | 10.46K | 5.36K | 13.07K | 14.72K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -2.65M | -4.03M | -5.05M | -3.13M | -3.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 8.70K | 28.98K | 3.18K | 3.18K | 0 |
| Net Income | -1.51M | -1.47M | -88.05K | -4.92M | -1.53M | -1.74M | -2.29M | -1.96M | -2.11M | -2.00M | -2.66M | -4.06M | -5.05M | -3.14M | -3.63M |
| Diluted EPS | - | - | -0.03 | -1.17 | -0.18 | -0.20 | -0.26 | -0.20 | -0.19 | -4.84 | -4.80 | -5.10 | -4.74 | - | -0.81 |
| R&D Expense | 330.77K | 279.85K | 248.42K | 319.74K | 369.62K | 335.12K | 330.38K | 393.64K | 402.43K | 274.50K | 367.39K | 311.37K | 330.59K | - | 349.71K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 4.80K | 2.53M | 9.36M | 6.16M |
| Gross Profit | - | 4.34K | - | - | - |
| Operating Income | -2.21M | -4.01M | -7.97M | -8.95M | -10.57M |
| Net Income | -6.33M | -8.15M | -7.94M | -9.04M | -14.91M |
| Diluted EPS | - | -1.81 | -0.91 | -22.50 | -8.66 |
| R&D Expense | 1.01M | 1.38M | 1.47M | 1.46M | 1.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 1.45M | 12.18M | 8.22M | 6.51M | 10.96M |
| Total Equity | -15.07M | -15.79M | 11.04M | 4.86M | 2.60M | 7.28M |
| Cash & Equivalents | - | 1.36M | 11.41M | 2.82M | 1.11M | 6.45M |
| Total Liabilities | - | 13.20M | 1.14M | 3.37M | 3.91M | 3.68M |
| Current Liabilities | - | 13.04M | 1.14M | 2.25M | 3.10M | 2.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -2.05M | -4.07M | -6.04M | -7.26M | -9.33M |
| Investing Cash Flow | - | -219.99K | -2.21M | -79.08K | -60.57K |
| Financing Cash Flow | 3.33M | 14.34M | -344.98K | 5.63M | 14.73M |
| Capital Expenditure | - | -219.99K | -22.90K | -79.08K | -60.57K |
| Free Cash Flow | - | -4.29M | -6.06M | -7.34M | -9.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 90.3% | - | - | - |
| Operating Margin % | - | -83,511.5% | -314.8% | -95.6% | -171.6% |
| Net Margin % | - | -169,771.2% | -313.4% | -96.6% | -242.0% |
| ROE % | 40.1% | -73.8% | -163.5% | -347.4% | -204.9% |
| ROCE % | 19.0% | -36.3% | -133.5% | -262.7% | -131.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIAF
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNSWdKRkxLZTItekYtQ0dhbDFGQTBibEZVeEU0Y2ZRNDAwcE5WWGx6TXI0UTN6LWRWWFdFM3ZfNzhGTndVdXp4OUZsTGN0N0FWS3BVTDFnTElwRm1EUjZDazF4dFVfSUtVN3dTelFYek9SeGlmVDBqZ2VKZlROLXk5aXJUV3dIbGhab0pqdg…
Enterprise value to EBIT forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYVR1WGlxamdqVGZkTWxDTWVDWWI3OFg1bE1iMjFFS19yeFQtYUhOMktuTl81UGljNE8zRHY1b2dvVHBacVhtcVFoNWM2Vzc4LWZKc3hvck5GTDJmeVdZc3BXdnl4UW9kOGlYZE9hYXJUMXFjaVZfVi1wdk1aa2R4akxTdGNuNkxoWW5pVH…
A lung test framework spans nodule evaluation and cancer follow-up - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNYnU1LWYwWHFRS2U3QXo3QUpBRFNxeHZCUEFoRlNjd0QzXzlsY29RWHNFejA4cU1qdHRfUFBjN2ozZ3VOVXctVjJhOFp2QTZJQVpLc1JKVkpwblNDUlVOTFloT29kYkhoYzB1UUhzS1dpSVlTZlUzVWdWb0dwYmxZd2oyM3U4VHdfTE1mam…
BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally - Stocktwits
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQMGNHbUJVbzgxTDZ4WjhIOWRaQTlnTm5KZmVLclRGNkF4QTJZVGo4N3lSU3lDQldTRVI4UnVEcS1RSEpIMF9NTU5iOVp2RjlOQ2o3aV84eTVHNGVJcWsxMDFRUklaNkxMRGRSMVNldzg5MDhEZlk2WjNFWFo4UVNlc0FraFM4UzFpdXY2ZE…
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNLWZJY3VMcEJhcjczQ1FuaFotTGl2YWlQVHNKMm5FV1R2TjRpdUpUbVhDLXFFdWsxcWZMUGxGMllOdVpLbjlONndFejFZR3puUWlDckdleEdaVUJNQVFMZzhBajlHdWZCb0p6MVJPbHU3aFBMZGhDS1drX0RkSE5XZ2thbWh6NkZObUhLZk…
bioAffinity Tests Under Development Aim to Personalize Asthma, COPD Treatment - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNM0l0NUxqeEhwUGJ4bkZIREpSbjFxaUJzVzNNVDdOc3pGTHRxVnI2eUN5Zlg4VnZicVRUSk5pdjF6bHJlOER3MTNibl9ZS1R3aTZVTG1PaTdLM1NQem9HXzdFS2Q0YjY4dlpDbk5hUzViTGNEaVVKSXBaeUN5VVNtQzMtNjBJb2ZMdk5zRj…
BIAF — Frequently Asked Questions
What is the current share price of BIAF?
As of 2026-08-05 17:25 PDT, BIAF trades at $0.53 on NASDAQ/NYSE. Its 52-week range is $0.53 to $10.50.
What is the P/E ratio of BIAF?
BIAF trades at a trailing price-to-earnings (P/E) ratio of -0.06.
Is BIAF a good stock to buy?
This page provides a data-driven analysis of BIAF, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.